Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody: collagenase clostridium histolyticum, ocriplasmin | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 28 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 10851
Sealed predictions
- COL1A2 in dopamine neurons, braak+0.17 (p 0.654) → -0.04 (p 0.927)receipt 10859
Swarm cases
receipt 10859: COL1A2 in dopamine neurons, braak
- power
- full sample +0.02 (p 0.949, n 18), 95% CI -0.45 to +0.48. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.983, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.04 (p 0.874, n 18). could be the mix.
- skeptic
- leave-one-out range -0.08 to +0.14, sign flips 7; without severely affected donors +0.02 (p 0.949, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for COL1A2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts